M Partridge
Overview
Explore the profile of M Partridge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
992
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gorovits B, Hays A, Jani D, Jones C, King C, Lundequist A, et al.
AAPS J
. 2021 Mar;
23(2):34.
PMID: 33649990
In May 2020, the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) published a recommendation report entitled "Recommendation on nonanimal-derived antibodies". In this report, the EURL ECVAM specifically...
2.
Holyoake D, Warren D, Hurt C, Aznar M, Partridge M, Mukherjee S, et al.
Clin Oncol (R Coll Radiol)
. 2018 Apr;
30(7):418-426.
PMID: 29602584
Aims: Gastrointestinal toxicity impedes dose escalation in chemoradiotherapy for hepatobiliary malignancies. Toxicity risk depends on clinical and radiotherapy metrics. We aimed to identify predictive factors using data from two prospective...
3.
Reeve M, Partridge M
Ann Entomol Soc Am
. 2018 Mar;
110(5):449-456.
PMID: 29563645
Research-isolation is a common problem affecting many researchers who are disconnected from their research communities. It can be caused by a number of factors, including physical isolation, unfamiliar research topics,...
4.
Buettner F, Alexander E, McNair H, Bulbrook L, Gulliford S, Partridge M, et al.
Med Phys
. 2017 May;
39(6Part13):3762.
PMID: 28517352
Purpose: To investigate the effects of an endorectal device during prostate radiotherapy on the spatial distribution of dose to the ano-rectal region and quantify implications for normal-tissue-complication probabilities. Methods: Twenty-three...
5.
Wilson J, Mukherjee S, Brunner T, Partridge M, Hawkins M
Clin Oncol (R Coll Radiol)
. 2017 Feb;
29(6):370-377.
PMID: 28190636
Aims: A proportion of patients with pancreatic cancer never develop metastatic disease. We evaluated a role for F-fluorodeoxyglucose positron emission tomography (FDG-PET) in identifying a subset of patients with locally...
6.
Witztum A, George B, Warren S, Partridge M, Hawkins M
Med Phys
. 2016 Nov;
43(11):6009.
PMID: 27806596
Purpose: Toxicity dose-response models describe the correlation between dose delivered to an organ and a given toxic endpoint. Duodenal toxicity is a dose limiting factor in the treatment of pancreatic...
7.
Riches S, Payne G, Morgan V, Dearnaley D, Morgan S, Partridge M, et al.
Eur Radiol
. 2015 Mar;
25(5):1247-56.
PMID: 25749786
Objectives: The objectives are determine the optimal combination of MR parameters for discriminating tumour within the prostate using linear discriminant analysis (LDA) and to compare model accuracy with that of...
8.
Timlin C, Warren D, Rowland B, Madkhali A, Loken J, Partridge M, et al.
Med Phys
. 2015 Feb;
42(2):866-76.
PMID: 25652499
Purpose: Tools for comparing relative induced second cancer risk, to inform choice of radiotherapy treatment plan, are becoming increasingly necessary as the availability of new treatment modalities expands. Uncertainties, in...
9.
Subiel A, Moskvin V, Welsh G, Cipiccia S, Reboredo D, Evans P, et al.
Phys Med Biol
. 2014 Sep;
59(19):5811-29.
PMID: 25207591
Very high energy electrons (VHEE) in the range from 100-250 MeV have the potential of becoming an alternative modality in radiotherapy because of their improved dosimetry properties compared with MV...
10.
Wilson J, Partridge M, Hawkins M
Clin Oncol (R Coll Radiol)
. 2014 Jul;
26(9):581-96.
PMID: 24998430
Functional imaging gives information about physiological heterogeneity in tumours. The utility of functional imaging tests in providing predictive and prognostic information after chemoradiotherapy for both oesophageal cancer and pancreatic cancer...